NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
19 trialsNCT07340515 2026-01-14
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Shandong Cancer Hospital and Institute
Phase 3 Recruiting
NCT07111832 2025-12-18
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07251582 2025-11-26
LungTime-C02
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT06235203 2025-06-03
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Eye & ENT Hospital of Fudan University
Phase 3 Recruiting
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06712888 2025-03-18
Navigation
Sun Yat-sen University
Phase 3 Recruiting
NCT06437977 2025-03-13
neoR-TORCH
Shanghai Chest Hospital
Phase 3 Recruiting
NCT06170489 2025-02-28
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06592326 2024-09-19
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06095583 2024-06-21
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06277050 2024-04-30
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 3 Recruiting
NCT06201065 2024-01-11
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT05302284 2023-12-18
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06026878 2023-09-07
GNT Induction Treatment in Locally Advanced NPC
Air Force Military Medical University, China
Phase 3 Recruiting
NCT05340491 2022-08-31
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT04376866 2021-07-20
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Cancer Hospital of Guangxi Medical University
Phase 3 Recruiting
NCT04778956 2021-03-04
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04453813 2020-09-28
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting